HTS fluorescence polarization assay for inhibitors of Keap1-Nrf2 interaction

Keap1-Nrf2 相互作用抑制剂的 HTS 荧光偏振测定

基本信息

  • 批准号:
    8204553
  • 负责人:
  • 金额:
    $ 3.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-12-03 至 2012-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): HTS fluorescence polarization assay for inhibitors of Keap1-Nrf2 interaction Keap1-Nrf2-antioxidant response element (ARE) system regulates cellular defense mechanisms that protect cells from oxidative stress. Indirect inhibitors of Keap1-Nrf2 interaction such as sulforaphane, curcumin, and epigallocatechin gallate are being tested as chemopreventive agents. However, there are general concerns over their use as chemopreventive agents because of their chemical reactivity and their putative irreversible mechanism of action. High throughput screening of chemical libraries is an effective approach to discover small molecule leads as direct reversible inhibitors of protein-protein interactions like Keap1-Nrf2; such direct inhibitors of Keap1-Nrf2 interaction would address concerns over the general use of purified natural thiol- reactive inhibitors as chemopreventive agents. The goal of this current application is to translate our fluorescence polarization (FP) assay to a MLPCN screening center for the screening of MLPCN library. The FP assay detects competitive inhibitors of a fluorescently labeled-Nrf2 peptide from binding to Keap1 kelch domain. Funding for the development of the fluorescent probe and the FP assay has been provided in part by R01 CA133791, Hu L (PI). Secondary and tertiary assays have been established in our labs including an SPR binding assay and a cell-based ARE-luciferase reporter assay. Limited chemical modification will also be performed in the second year to derive initial SAR to enable the selection of hits as leads for future optimization into potent direct inhibitors of Keap1-Nrf2 interaction. Such inhibitors will be useful as important pharmacological probes for the elucidation of cytoprotective pathways and as potential chemopreventive agents of cancer and other diseases in high risk populations. PUBLIC HEALTH RELEVANCE: Screening of the MLPCN library with our high throughput fluorescence polarization assay will enable the discovery of novel small molecules as direct inhibitors of Keap1-Nrf2 interaction. Specific and potent Keap1- Nrf2 inhibitors will be useful as important pharmacological probes for the elucidation of cytoprotective pathways and as potential cancer chemopreventive agents in high risk populations.
描述(由申请人提供):Keap1-Nrf2相互作用抑制剂的HTS荧光偏振测定Keap1-Nrf2抗氧化反应元件(ARE)系统调节细胞防御机制,保护细胞免受氧化应激。Keap1-Nrf2相互作用的间接抑制剂,如萝卜硫素、姜黄素和表没食子儿茶素没食子酸酯正在作为化学预防剂进行测试。然而,由于其化学反应性和假定的不可逆作用机制,人们普遍担心将其用作化学预防剂。高通量筛选化学文库是发现小分子先导物作为蛋白质相互作用的直接可逆抑制剂(如Keap1-Nrf2)的有效方法;这种Keap1-Nrf2相互作用的直接抑制剂将解决一般使用纯化的天然硫醇反应性抑制剂作为化学预防剂的问题。本应用的目的是将我们的荧光偏振(FP)分析转化为MLPCN筛选中心,用于MLPCN文库的筛选。FP分析检测荧光标记的nrf2肽与Keap1 kelch结构域结合的竞争性抑制剂。开发荧光探针和FP测定的部分资金由R01 CA133791, Hu L (PI)提供。我们的实验室已经建立了二级和三级检测,包括SPR结合检测和基于细胞的are -荧光素酶报告基因检测。有限的化学修饰也将在第二年进行,以获得初始SAR,以便选择命中点作为未来优化成Keap1-Nrf2相互作用的有效直接抑制剂的先导。这些抑制剂将成为阐明细胞保护途径的重要药理学探针,并在高危人群中作为癌症和其他疾病的潜在化学预防剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LONGQIN HU其他文献

LONGQIN HU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LONGQIN HU', 18)}}的其他基金

L-Cystine Diamides as Inhibitors of L-Cystine Stone Formation in Cystinuria
L-胱氨酸二酰胺作为胱氨酸尿症中 L-胱氨酸结石形成的抑制剂
  • 批准号:
    10083210
  • 财政年份:
    2017
  • 资助金额:
    $ 3.86万
  • 项目类别:
HTS fluorescence polarization assay for inhibitors of Keap1-Nrf2 interaction
Keap1-Nrf2 相互作用抑制剂的 HTS 荧光偏振测定
  • 批准号:
    8070110
  • 财政年份:
    2010
  • 资助金额:
    $ 3.86万
  • 项目类别:
Optimization of EphA subtype-selective antagonists as probes for the nervous syst
EphA亚型选择性拮抗剂作为神经系统探针的优化
  • 批准号:
    7936819
  • 财政年份:
    2009
  • 资助金额:
    $ 3.86万
  • 项目类别:
Homogenous HTS Assays to Screen for Inhibitors of Keap1-Nrf2 Interaction
用于筛选 Keap1-Nrf2 相互作用抑制剂的同质 HTS 测定
  • 批准号:
    7902191
  • 财政年份:
    2008
  • 资助金额:
    $ 3.86万
  • 项目类别:
Homogenous HTS Assays to Screen for Inhibitors of Keap1-Nrf2 Interaction
用于筛选 Keap1-Nrf2 相互作用抑制剂的同质 HTS 测定
  • 批准号:
    7691725
  • 财政年份:
    2008
  • 资助金额:
    $ 3.86万
  • 项目类别:
Novel Keap1-Nrf2 Inhibitors as Chemopreventive Agents
作为化学预防剂的新型 Keap1-Nrf2 抑制剂
  • 批准号:
    7321003
  • 财政年份:
    2007
  • 资助金额:
    $ 3.86万
  • 项目类别:
Novel Keap1-Nrf2 Inhibitors as Chemopreventive Agents
作为化学预防剂的新型 Keap1-Nrf2 抑制剂
  • 批准号:
    7455941
  • 财政年份:
    2007
  • 资助金额:
    $ 3.86万
  • 项目类别:
Structure-Based Design of Eph Receptor Antagonists
Eph 受体拮抗剂的基于结构的设计
  • 批准号:
    6861086
  • 财政年份:
    2004
  • 资助金额:
    $ 3.86万
  • 项目类别:
Structure-Based Design of Eph Receptor Antagonists
Eph 受体拮抗剂的基于结构的设计
  • 批准号:
    6718126
  • 财政年份:
    2004
  • 资助金额:
    $ 3.86万
  • 项目类别:
MECHANISM BASED INHIBITION OF CYCLIN DEPENDENT KINASES
基于机制的细胞周期依赖性激酶抑制
  • 批准号:
    6090936
  • 财政年份:
    2000
  • 资助金额:
    $ 3.86万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 3.86万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 3.86万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 3.86万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 3.86万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了